Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novartis AG Common Stock (NY:NVS)

159.48 +1.46 (+0.92%)
Streaming Delayed Price Updated: 10:23 AM EDT, Aug 25, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novartis AG Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
58 59 Next >
News headline image
VIG, VYM, and VYMI: Which Vanguard Dividend ETF Is Right for You? ↗
Vanguard offers three dividend ETFs—VIG, VYM, and VYMI—with distinct yields, holdings, and geographic focus, giving income investors varied ways to access dividend-paying stocks. 
Via MarketBeat
Topics ETFs
News headline image
Breakfast News: A Conversation With Ionis CEO ↗
Ionis Pharmaceuticals CEO on a major profitability milestone, breakthrough medicines and more. 
Via The Motley Fool
Topics ETFs World Trade
Novartis (NYSE:NVS): A Dividend Quality Play for Income Investors ↗
Via Chartmill
News headline image
Which Healthcare ETF Is the Better Buy: VanEck's Pharma PPH or State Street's Biotech XBI? ↗
PPH offers the income and stability of proven pharmaceutical leaders while XBI swings for the fences across 155 smaller biotech names. 
Via The Motley Fool
Topics ETFs
Novartis (NYSE:NVS): A Top Dividend Stock with Strong Fundamentals and Sustainable Payouts ↗
Via Chartmill
NOVARTIS AG-SPONSORED ADR (NYSE:NVS): High-Quality Dividend Stock With Strong Profitability and Sustainable Payout ↗
Via Chartmill
News headline image
PPH vs. IYH: Which Healthcare Fund Is the Better Buy? ↗
PPH concentrates on just 26 drugmakers, while IYH diversifies more broadly across 100 healthcare holdings. 
Via The Motley Fool
Topics ETFs
News headline image
This ETF Is Outperforming by Avoiding the S&P 500’s Biggest Problem ↗
The JPMorgan International Value ETF (JIVE) has outpaced the S&P 500 this year, offering low-volatility, diversified international exposure with a 1.22% yield and rising institutional demand. 
Via MarketBeat
Topics Artificial Intelligence ETFs Stocks
News headline image
The L.A. Lakers Delivered a 1-Year Return of 25%. These ETFs Have Done Even Better. ↗
Most people don't have $12.5 billion to buy the L.A. Lakers. But with stock ETFs, you could earn a higher return than the Lakers' owners. 
Via The Motley Fool
Topics Artificial Intelligence ETFs Economy
News headline image
Vanguard Is Bullish on Developed Markets Outside the U.S. -- But How Can You Buy Them? These 2 ETFs Can Help. ↗
Want to put your money into global stocks that might be big winners from AI? These two low-cost ETFs offer international diversification. 
Via The Motley Fool
Topics Artificial Intelligence ETFs Economy
News headline image
VanEck Pharmaceutical ETF vs. Invesco Biotech ETF: Which Fund Fits Your Investing Style? ↗
VanEck targets established pharma giants with lower costs and volatility, while Invesco pursues high-growth biotech companies. One delivered stronger returns; the other weathered downturns better. 
Via The Motley Fool
Topics ETFs
News headline image
3 Dividend Stocks to Buy for a Lifetime of Passive Income ↗
These companies' recent headwinds shouldn't lead to decreased payouts. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Concentrated Pharma Exposure or Broader Global Healthcare? PPH vs. IXJ ↗
The VanEck Pharmaceutical ETF (PPH) gives investors a concentrated way to own major drugmakers, while the iShares Global Healthcare ETF (IXJ) spreads exposure across the wider healthcare sector. The... 
Via The Motley Fool
Topics ETFs
News headline image
Novartis (NVS) Q2 2026 Earnings Call Transcript ↗
Growth drivers offset generic erosion as priority brands surge 36% in constant currency. 
Via The Motley Fool
Topics Earnings
News headline image
Novartis Q2 Earnings Call Highlights ↗
Novartis (NYSE:NVS) said it returned to sales growth in the second quarter of 2026, supported by strong gains across priority medicines and launches, while reaffirming its full-year outlook despite... 
Via MarketBeat
Topics ETFs Earnings
News headline image
Novartis Q2 2026 Earnings Call Transcript ↗
Novartis (NYSE:NVS) reported second-quarter financial results on Tuesday. The transcript from the company's second-quarter earnings call has been provided below. Benzinga APIs provide real-time access... 
Via Benzinga
Topics Earnings
News headline image
Novartis Bounds For Buy Point. Why Shares Are On The Rise. ↗
Novartis stock jumped early Tuesday on better-than-expected second-quarter metrics, partially driven by Cosentyx. 
Via Investor's Business Daily
News headline image
Novartis Silences Generic Fears With Blowout Quarter, Packed Pipeline ↗
Novartis shares rise as strong Q2 demand for key growth drugs offsets generic competition. NVS beats Q2 earnings and reaffirms 2026 targets. 
Via Benzinga
News headline image
For Global Pharma Exposure Is the VanEck Pharmaceutical ETF or iShares Healthcare Fund the Better Buy in 2026? ↗
PPH's concentrated 26-stock portfolio delivered 28% returns over one year, while its 2% dividend yield beats IXJ by 50 basis points. 
Via The Motley Fool
Topics ETFs
News headline image
This Novartis Drug Could Help Delay Dialysis—FDA Grants Full Approval ↗
Novartis wins traditional FDA approval for Fabhalta, a first-in-class oral treatment slowing kidney decline in adult IgAN. 
Via Benzinga
News headline image
StreetWatch: Nuvectis Pharma Eyes $9.8 Billion Oral PNH Market With Late-Stage NXP100 Backed by Strong Positive Phase 3 Data
New report covers Nuvectis Pharma (NASDAQ: NVCT) as the company transitions from a single-drug oncology story into a late-stage rare-disease... 
Via Newsfile
News headline image
Global Nitrogen-Containing Bisphosphonate Drugs Market Growing at 3.1% CAGR Through 2032 ↗
According to a new report from Intel Market Research, the global Nitrogen-Containing Bisphosphonate Drugs Market was valued at USD 3.65 billion in 2024 and 
Via Talk Markets
News headline image
Novartis vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026? ↗
Novartis boasts a 26% net margin and a fortress balance sheet, while Teva's turnaround has returned it to profitability, but at what cost to stability? 
Via The Motley Fool
News headline image
What Is the Vanguard International Dividend Appreciation ETF (VIGI), and Who Should Buy It? ↗
Not every international ETF is a can't-miss investment opportunity. 
Via The Motley Fool
Topics ETFs Economy
News headline image
Vanguard Health Care vs. VanEck Pharmaceutical: How Do These ETFs Stack Up? ↗
VHT offers broad diversification across 429 healthcare holdings, while PPH concentrates on 26 drugmakers for higher growth potential. 
Via The Motley Fool
Topics ETFs
News headline image
VYMI vs. VIGI: Which International Dividend ETF Is Better? ↗
When buying international dividend stocks, diversification is likely the best bet. 
Via The Motley Fool
Topics Artificial Intelligence ETFs
News headline image
2 Fast-Growing Pharmaceutical Stocks to Buy Now ↗
Incyte and TG Therapeutics are seeing strong share growth, backed up by booming revenue and earnings. 
Via The Motley Fool
News headline image
The Market Just Got Shaken—These 3 ETFs May Come Out Stronger ↗
As Middle East tensions resurface and futures drop, VIG, VIGI, and FDVV offer dividend growth ETFs combining income with exposure to technology and global equities. 
Via MarketBeat
Topics Artificial Intelligence ETFs Stocks
MissionIRNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Shareholders Should Watch Novartis Latest $1.5 Billion ADC Acquisition
Via Investor Brand Network
News headline image
Novartis Scoops up UK Biotech Myricx in $1.5 Billion Cancer Push ↗
Novartis acquires Myricx Bio for up to $1.5B to boost its oncology pipeline with a novel next-gen ADC cancer platform. Read more. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
58 59 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.